Announcements Trials
Browse Landscape

Phase

Phase 2 43Phase 1 32Phase 1/2 22Phase 3 18Phase NA 14Phase 2/3 5Phase 4 2Phase EARLY_PHASE1 1

Status

Terminated 1Completed 1

Sponsor Class

INDUSTRY 2

Study Type

Interventional 2

Sponsor

Cancer Type

Lymphoid 2Classical hematology 1

Conditions

Precursor Cell Lymphoblastic Leukemia-Lymphoma 60Lymphoma 35Lymphoma, Follicular 31Lymphoma, Non-Hodgkin 30Leukemia, Lymphocytic, Chronic, B-Cell 16Recurrence 11Lymphoma, Large B-Cell, Diffuse 11Leukemia 11Lymphoma, B-Cell 10Waldenstrom Macroglobulinemia 8Lymphoma, T-Cell, Cutaneous 8Hodgkin Disease 8Mycosis Fungoides 6Lymphoma, Mantle-Cell 6Neoplasm, Residual 5Lymphoma, T-Cell, Peripheral 5Lymphoma, T-Cell 5Lymphoma, Extranodal NK-T-Cell 5Febrile Neutropenia 5Burkitt Lymphoma 5Asthma 5Pain 4Neoplasms 4Multiple Myeloma 4Lymphoma, Large-Cell, Anaplastic 4Leukemia, Myeloid, Acute 4Hematologic Diseases 4Sezary Syndrome 3Neoplasms, Plasma Cell 3Myelodysplastic Syndromes 3

Interventions

ferric carboxymaltose 1Brentuximab Vedotin 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Phase 4 × Lymphoproliferative Disorders × Lymphoid × Clear all
NCT01100879 2022-05-09

AOC-MM

Vifor Pharma

Phase 4 Terminated
3 enrolled
Classical hematologyLymphoid

Anemia, Lymphoproliferative Disorders, Anemia, Iron-Deficiency

NCT01990534 2021-04-09

A Study of Brentuximab Vedotin in Participants With Relapsed or Refractory Hodgkin Lymphoma

Takeda

Phase 4 Completed
60 enrolled 21 charts
Lymphoid

Hematologic Diseases, Hodgkin Disease, Immune System Diseases, Immunoproliferative Disorders, Lymphatic Diseases, Lymphoma, Lymphoproliferative Disorders, Neoplasms, Neoplasms by Histologic Type, Recurrence, Lymphoma, B-Cell, Lymphoma, T-Cell, Lymphoma, Large B-Cell, Diffuse

Data powered by HemOnc (CC BY 4.0) Colophon âš¡